INFU Earnings

INFU reported its earnings on 2026-05-07, showcasing a revenue of 33.68M against an estimate of 34.50M, resulting in a -2.37% surprise. The EPS was 0.05, surpassing the expected 0.04 by 25%. The stock experienced a -11.54% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following INFU's earnings announcement on 2026-05-07, the stock price moved by -11.54% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, INFU's stock price tends to shift by an average of 6.54% in the 10 days leading up to earnings and 2.06% in the 10 days following, providing insight into potential market.

For 2026/Q2, analysts estimate INFU's annual revenue to reach 37.09M, while the EPS is projected at 0.11. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between INFU's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, INFU's stock price typically moves by 6.54% in the 10 days before its earnings and 2.06% in the 10 days after. For the upcoming 2026/Q2 earnings, analysts expect an EPS of 0.11 and revenue of 37.09M.

The earnings call presented a mixed picture: while there were positive developments such as strong growth in wound care and improved gross margins, these were offset by challenges like decreased device solutions revenue and increased net debt. The Q&A session revealed some uncertainties, particularly around ERP implementation and oncology RCM migration, but also highlighted strategic partnerships and market optimism. Overall, the sentiment is neutral due to balanced positive and negative factors, with no clear catalyst for significant stock movement in either direction.